--- title: "U.S. stock market midday update: Exicure up 15.29% with increased volume, active funds without positive drivers" type: "News" locale: "en" url: "https://longbridge.com/en/news/292222823.md" description: "Exicure rose 15.29%; Alibaba's Arm Pharmaceuticals rose 3.04%, with a transaction volume of USD 1.342 billion; Bridgebio Pharma rose 14.48%, with a transaction volume of USD 839 million; Ionis Pharmaceuticals fell 22.20%, with a transaction volume of USD 760 million; AbbVie fell 0.99%, with a market value of USD 442.1 billion" datetime: "2026-07-09T16:07:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292222823.md) - [en](https://longbridge.com/en/news/292222823.md) - [zh-HK](https://longbridge.com/zh-HK/news/292222823.md) generator: "portal-rs" --- # U.S. stock market midday update: Exicure up 15.29% with increased volume, active funds without positive drivers **U.S. Stock Market Midday Update** Exicure, up 15.29%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks Ranked High in Industry Trading Volume** Alnylam Pharmaceuticals up 3.04%. Based on recent key news: 1. On July 9, AstraZeneca's drug Wainua, developed in collaboration with Ionis, failed to meet its primary endpoint in late-stage trials, leading to stock price increases of 18% and 15% for Alnylam Pharmaceuticals and BridgeBio, respectively. This outcome is favorable for Alnylam Pharmaceuticals as the failure of its market competitor enhances its market position. Source: MarketWatch 2. On July 9, analysts pointed out that AstraZeneca's trial failure could damage its reputation, while Alnylam Pharmaceuticals' drug performed well in the same field, further boosting investor confidence. Source: MarketWatch 3. On July 9, Alnylam Pharmaceuticals' trading volume significantly increased to $1.342 billion, indicating strong market interest in its stock. Source: MarketWatch The gene therapy market is highly competitive, and investors should be cautious. BridgeBio Pharma up 14.48%. Based on recent key news: 1. On July 9, Ionis Pharmaceuticals' neurology drug Wainua failed to meet its primary endpoint in late-stage trials, causing its stock to drop by 21.8%. This failure is favorable for BridgeBio Pharma, as its drug for the same disease has been approved, driving its stock price up by about 15%. 2. On July 8, JP Morgan initiated coverage on BridgeBio Oncology stock with an "Overweight" rating and a target price of $27. This positive rating propelled the stock price upward. 3. On July 9, AstraZeneca's gene-silencing drug trial failed, leading to a drop in its stock price. This news is favorable for BridgeBio as it reduces competition for similar drugs in the market, further driving the stock price up. The competition in the gene therapy field is intensifying, and market volatility is evident. Ionis Pharmaceuticals down 22.20%. Based on recent key news: 1. On July 9, Ionis Pharmaceuticals' eplontersen, developed in collaboration with AstraZeneca, failed to meet its primary efficacy endpoint in the Phase 3 CARDIO-TTRansform study for the ATTR-CM indication. The drug did not significantly reduce cardiovascular risk in patients, leading to a pre-market drop of over 21% in its stock price. 2. On July 9, AstraZeneca's neurology drug Wainua, developed in collaboration with Ionis, failed to meet its primary goals of reducing cardiovascular mortality and recurrent cardiac issues in late-stage trials Analysts predict that the peak sales opportunity for the drug could reach $2 billion, and the trial failure has dealt a significant blow to the company. On July 9, analysts pointed out that the trial failure could damage the credibility of AstraZeneca's management, leading to a reassessment of Ionis's long-term opportunities, with the stock price being severely affected. The overall industry performance is weak, with significant capital outflows. **Stocks ranked at the top of the industry by market capitalization** AbbVie fell 0.99%. Based on recent key news: 1. On July 7, the European Commission approved AbbVie's Tepkinly combination for the treatment of follicular lymphoma. This approval makes the combination a chemotherapy-free bispecific treatment option in the European market, significantly enhancing AbbVie's market position in this field and driving stock price volatility. 2. On July 7, AbbVie announced its second-quarter earnings expectations, including $291 million in research and milestone expenses, which will impact GAAP and non-GAAP earnings per share by $0.17. This news raised concerns in the market about the company's profitability, leading to a decline in stock price. 3. On July 9, Morgan Stanley raised AbbVie's target price to $279, expecting the company's second-quarter revenue to exceed market consensus, but earnings per share to be slightly below expectations. The analysts' rating adjustments have impacted the stock price. The fundamentals of the biopharmaceutical industry remain strong, with macro factors having a diminished impact ### Related Stocks - [XCUR.US](https://longbridge.com/en/quote/XCUR.US.md) - [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md) - [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md) - [IONS.US](https://longbridge.com/en/quote/IONS.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [Why the jobs report will actually be good for bonds](https://longbridge.com/en/news/298066649.md) - [The inflation genie could be out of the bottle — and bond markets are sounding the alarm](https://longbridge.com/en/news/297992868.md) - [Is The Bessent Put Landing In The Wrong Market?](https://longbridge.com/en/news/298063087.md) - [Cocoa Crashed This Year. So Why Is Your Halloween Candy Still This Pricey?](https://longbridge.com/en/news/298054892.md) - [Fed Chair Warsh Told Markets to Read Data. They Read Him Instead.](https://longbridge.com/en/news/298030286.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**